Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
This article provides guidance to advanced practice providers (e.g., nurses, nurse practitioners, physician assistants) and oncology pharmacists for the clinical management of key lorlatinib-emergent adverse reactions (i.e., hyperlipidemias, central nervous system effects, bodyweight increase, edema, and peripheral neuropathy). As lorlatinib is both a substrate and inducer of the CYP3A enzyme system and is contraindicated with strong CYP3A inducers, relevant drug-drug interactions are also highlighted.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Nurses | Nursing | Peripheral Neuropathy